

# Business Sale Overview Memo

## Project Resistance – Biopharmaceutical Company

<b>Acquisition Opportunity</b>	<p>A unique opportunity exists to purchase the intellectual property assets of an early-stage biopharmaceutical company (“Company”) that has been developing technology to address one of the world’s biggest threats to global health, antibiotic resistance.</p> <p>The Company’s patented technology uses DNA therapeutics which are administered before or with antibiotics to inactivate resistance in bacterial pathogens. Applicable to all antibiotic classes, resistance mechanisms and all bacteria, this technology makes existing antibiotics work again, prevent the spread of resistance genes and protects new antibiotics.</p> <p>The Company’s technology offers a low-cost solution to addressing resistance and rescuing antibiotics that no longer work, extend the ROI life of newly developed antibiotics and creates the opportunity to patent multiple products. The Company has already achieved proof of concept in animal models, and is in the testing phase for proof of concept in humans.</p> <p>Interested parties are requested to specifically deal and formally register their interest with Andrew Smith or Emily Muir at SIA Group, who are acting as Agents on behalf of the Company’s Joint Administrators.</p> <p>It is intended that a sale will be executed at the earliest opportunity and all expressions of interest must be registered by no later than <b>12 pm (BST), Tuesday 11th April 2023.</b></p>
<b>Intellectual Property - Assets Available</b>	<ul style="list-style-type: none"> <li>• Patent Portfolio &amp; Organisational Knowledge <ul style="list-style-type: none"> <li>○ The Company has filed two PCT patents, with notice of grant received in key commercial territories including US, EU, China, Japan, Australia and Hong Kong, and a number of territories still pending</li> <li>○ All associated research, test data and other organisational knowledge is readily available</li> </ul> </li> <li>• Brand Related Assets <ul style="list-style-type: none"> <li>○ Goodwill rights in the Company’s corporate and product brand names</li> <li>○ Website content, domain, social media assets</li> </ul> </li> </ul>
<b>High Level Financial Information</b>	<p>The Company is pre-revenue and has raised a total of £1m from four fundraising rounds</p> <p><i>Accounts available upon request and within the data room</i></p>
<b>Further Information</b>	<p>Requests for further information should be addressed to Andrew Smith or Emily Muir of SIA Group, who are acting as Agents on behalf of the Company’s Joint Administrators. Contact details have been provided below.</p> <p>Access to the data room will be provided on receipt of a signed NDA.</p> <p>All offers to be supported by proof of funding.</p>

For further information please contact:

Emily Muir  
SIA Group Asset Ingenuity Ltd  
T. +44 (0) 7442 936 429  
E. Emily.Muir@sia-group.co.uk

Andrew Smith  
Sia Group Asset Ingenuity Ltd  
T. +44 (0) 7425 755 485  
E. Andrew.Smith@sia-group.co.uk

